Click here to load reader

Annual Report 2018 annual report - MorphoSys · PDF file Annual Report 2018 2018 annual report MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany ... 2010, enables the precise

  • View
    12

  • Download
    1

Embed Size (px)

Text of Annual Report 2018 annual report - MorphoSys · PDF file Annual Report 2018 2018 annual report...

  • A nn

    ua l R

    ep or

    t 2 01

    8

    an nu

    al r

    ep o

    rt2018

    MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany Phone: +49-89-89927-0 Fax: +49-89-89927-222 www.morphosys.com

  • Product Pipeline MorphoSys’s Product Pipeline (December 31, 2018)

    M O S T A DVA N C E D D E V E LO P M E N T S TAG E

    P R O G R A M / PA R T N E R I N D I C AT I O N

    Tremfya®* (guselkumab) / Janssen/J&J Psoriasis

    Gantenerumab / Roche Alzheimer’s disease

    MOR208 / not partnered Hematological malignancies

    Anetumab ravtansine (BAY94-9343) / Bayer Solid tumors

    BAY1093884 / Bayer Hemophilia

    BHQ880 / Novartis Multiple myeloma

    Bimagrumab (BYM338) / Novartis Metabolic disease

    CNTO6785 / Janssen/J&J Inflammation

    Ianalumab (VAY736) / Novartis Inflammation

    MOR103 (GSK3196165) / GlaxoSmithKline Inflammation

    MOR106 / Novatis/Galapagos Inflammation

    MOR202 / I-Mab Biopharma** Multiple myeloma

    NOV-12 (MAA868) / Novartis Prevention of thrombosis

    Setrusumab (BPS804) / Mereo/Novartis Brittle bone syndrome

    Tesidolumab (LFG316) / Novartis Eye diseases

    M O S T A DVA N C E D D E V E LO P M E N T S TAG E

    P R O G R A M / PA R T N E R I N D I C AT I O N

    Utomilumab (PF-05082566) / Pfizer Cancer

    Xentuzumab (BI-836845) / BI Solid tumors

    BAY2287411 / Bayer Cancer

    Elgemtumab (LJM716) / Novartis Cancer

    MOR107*** (LP2-3) / not partnered Not disclosed

    NOV-7 (CLG561) / Novartis Eye diseases

    NOV-8 / Novartis Inflammation

    NOV-9 (LKA651) / Novartis Diabetic eye diseases

    NOV-10 (PCA062) / Novartis Cancer

    NOV-11 / Novartis Blood disorders

    NOV-13 (HKT288) / Novartis Cancer

    NOV-14 / Novartis Asthma

    PRV-300 (CNTO3157) / ProventionBio Inflammation

    Vantictumab (OMP-18R5) / OncoMed Solid tumors

    D IS

    C O

    V E

    R Y

    P R

    E C

    L IN

    IC

    P H

    A S

    E 1

    P H

    A S

    E 2

    P H

    A S

    E 3

    M A

    R K

    E T

    D IS

    C O

    V E

    R Y

    P R

    E C

    L IN

    IC

    P H

    A S

    E 1

    P H

    A S

    E 2

    P H

    A S

    E 3

    M A

    R K

    E T

    12 Programs

    14 Programs

    3 Programs*

    l e g e n d : mor progr am out- l icensed mor progr am partnered d iscovery progr am

    * We still consider Tremfya® a phase 3 compound due to ongoing studies in various indications. ** For development in China, Hong Kong, Taiwan, Macao. *** A phase 1 study in healthy volunteers was completed. MOR107 is currently in preclinical investigation with a focus on oncology indications.

    In addition, 6 proprietary programs and 56 partnered discovery programs are in discovery stage, 1 proprietary and 24 partnered discovery programs are in preclinic.

    phase 1 phase 2 phase 3

  • programs in

    phase 1

    programs in

    discovery

    programs in

    preclinic

    programs in

    phase 3

    programs in

    phase 2

    34 nations

    329 employees

    12 MOR Programs

    MorphoSys at a Glance Figures, data, facts (December 31, 2018)

    P R

    O D

    U C

    T P

    IP E

    LI N

    E –

    M O

    R P

    H O

    S Y

    S A

    T A

    G LA

    N C

    E

    r &

    d e

    x pe

    n se

    s (i

    n m

    il li

    o n

    € )

    62

    3

    25

    14 12

    More than

    70 active clinical studies with

    MorphoSys antibodies

    * We still consider Tremfya® a phase 3 compound due to ongoing studies in various indications. ** For development in China, Hong Kong, Taiwan, Macao. *** A phase 1 study in healthy volunteers was completed. MOR107 is currently in preclinical investigation with a focus on oncology indications.

    27.6

    106.4

    2008 2018

  • C O

    N T

    E N

    T S

    ENGINEERING THE MEDICINES OF TOMORROW

    Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach. Success is created by our employees, who focus on excellence in all they do and col- laborate closely across disciplines.

    FI N

    A N

    C IA

    L S

    TA T

    E M

    E N

    T S

    G R

    O U

    P M

    A N

    A G

    E M

    E N

    T R

    E P

    O R

    T

  • https://reports.morphosys.com/2018/

    Please find additional information in our online magazine.

  • Contents the company

    06 Roadmap 10 Clinical Development at MorphoSys 12 MorphoSys – A Strong Development Partner 14 Research at MorphoSys 16 Letter to the Shareholders

    group management report

    25 Operations and Business Environment 49 Operating and Financial Review and Prospects 63 Outlook and Forecast 67 Shares and the Capital Market 71 Sustainable Business Development 76 Risk and Opportunity Report 84 Statement on Corporate Governance,

    Group Statement on Corporate Governance and Corporate Governance Report

    113 Subsequent Events

    f inanc ial statements

    116 Consolidated Statement of Profit or Loss (IFRS) 117 Consolidated Statement of Comprehensive

    Income (IFRS)

    118 Consolidated Balance Sheet (IFRS) 120 Consolidated Statement of Changes in

    Stockholders’ Equity (IFRS)

    122 Consolidated Statement of Cash Flows (IFRS) 124 Notes 176 Responsibility Statement

    addit ional informat ion

    177 Independent Auditor’s Report 182 Report of the Supervisory Board 186 Supervisory Board of MorphoSys AG 188 Glossary 191 List of Figures and Tables 192 Imprint

    FI N

    A N

    C IA

    L S

    TA T

    E M

    E N

    T S

    G R

    O U

    P M

    A N

    A G

    E M

    E N

    T R

    E P

    O R

    T

  • As a fully inte- grated biopharma- ceutical company, we are driven by a desire to develop the medicines of tomorrow. The jour- ney towards this goal has been and continues to be exciting.

    Magaz ine

    4

    Roadmap

  • FI N

    A N

    C IA

    L S

    TA T

    E M

    E N

    T S

    G R

    O U

    P M

    A N

    A G

    E M

    E N

    T R

    E P

    O R

    T

    5

    Magaz ineRoadmap

  • the beginning: The company was founded in Martinsried near Munich.

    first ipo: MorphoSys AG goes public on the Frankfurt Stock Exchange in 1999. On September 6, 2004, the Company entered into the TecDAX and in 2018 to the MDAX.

    Since late 2016 the headquarters is located in

    Planegg near Munich

    1992

    antibody technology: In 2000, MorphoSys presented its HuCAL antibody library. This was followed by the HuCAL Gold antibody library (2001) and the HuCAL PLATINUM an- tibody library (2008). Ylanthia, the next generation of anti- body technologies, was launched in 2011. Slonomics, which has been part of the MorphoSys technology portfolio since 2010, enables the precise optimization of antibodies from the Ylanthia library.

    Magaz ine

    6

    Roadmap

    onl ine report

    https://www.morphosys.com/ company/history#roadmap

  • service and discovery partnerships: Initia- tion of a strategic partnership with Novartis in 2004, which expands into one of the largest antibody research collaborations in biotech and pharmaceuticals in 2007. MorphoSys has been researching and discovering anti- bodies on behalf of pharmaceutical partners since 1997. These include further partnerships with Bayer (1999), Roche (2000), Centocor (today: Janssen, 2000), Schering (2001) and Pfi zer (2003).

    Total Partnerships (as of Dec. 2018)

    a novel agent against alzheimer’s: In 2006 Partner Roche starts clinical development of a HuCAL anti- body against Alzheimer’s disease (gantenerumab). Six years later, gantenerumab became the fi rst MorphoSys antibody to enter late stage clinical development (phase 3). In 2018, new phase 3 trials where initiated to evaluate and approve gantenerumab in an optimized dosage regimen.

    proprietary drug development: The fi rst proprietary antibody MOR103 enters clinical develop- ment in 2008. In 2012, MorphoSys publishes positive study results with MOR103 in rheumatoid arthritis. The following year, MorphoSys signs a license agreement with GlaxoSmithKline for MOR103. In 2018, GlaxoSmith- Kline presents positive data from a phase 2 trial in rheumatoid arthritis patients.

    22

    development of mor208 : In 2010, MorphoSys signs a license agreement with Xencor Inc. for MOR208. In the same year, MorphoSys starts clinical development of the antibody. The fi rst positive data on MOR208 where presen- ted in 2012. In 2017, the U.S. Food and Drug Administra- tion awarded MOR208 breakthrough therapy designation in the blood cancer indication of diffuse larg

Search related